<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247867</url>
  </required_header>
  <id_info>
    <org_study_id>RIIDTOXINS</org_study_id>
    <nct_id>NCT04247867</nct_id>
  </id_info>
  <brief_title>Combination of Medium Cut-off Dialyzer Membrane and Diet Modification to Alleviate Residual Uremic Syndrome of Dialysis Patients</brief_title>
  <official_title>Combination of Medium Cut-off Dialyzer Membrane and Diet Modification to Alleviate Residual Uremic Syndrome of Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ljubljana, Faculty of Sport</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare achieved levels of protein-bound uremic toxins with dialysis using a
      medium cut-off membrane compared to the treatment by online haemodiafiltration with a
      high-flux dialysis membrane. In the second phase of the study dietary fiber and short-chain
      fatty acid intake will be increased to verify a possible additional reduction in the levels
      of protein bound uremic toxins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will carry out a prospective interventional randomised study to compare
      achieved serum concentrations of selected protein bound uremic toxins by dialysis with a
      medium cut-off membrane (Theranova, Baxter AG, USA) and online hemodiafiltration with a
      standard &quot;high-flux&quot; dialysis membrane. In the second phase, both dialysis purification
      methods will be supplemented by a change in the diet with increase of the daily intake of
      dietary fiber to 30g and addition of a short-chain fatty acid propionate in the dose of 1 g
      daily.

      The main outcome of the study is the serum concentration of p-cresol sulphate. Secondary
      outcome is the serum concentration of indoxyl-sulphate and trimethylamine-N-oxide (TMAO).
      Serum albumin concentration and lean body weight of patients represent safety outcomes for
      this study.

      This investigator-initiated research project has been entirely planned and will be conducted
      by the clinical researchers in a tertiary University Medical Center Ljubljana.

      The study will include 50 chronic prevalent stable dialysis patients in the following
      periods:

        -  2 weeks of wash-in period with standard bicarbonate haemodialysis and standard high-flux
           dialysis membrane,

        -  then the patients will be randomized in a 1:1 ratio to either one of the two study arms:

        -  (interventional study arm) 4 weeks of dialysis with medium cut-off (Theranova) membrane
           (first phase), then dialysis for 4 weeks with the same membrane and increased fiber
           intake (second phase),

        -  (control study arm) 4 weeks of dialysis with a high-flux membrane using on-line
           haemodiafiltration (first phase) and 4 weeks of high-flux membrane haemodiafiltration
           and increased fiber intake (second phase),

        -  finally, all patients will undergo a 4 week wash-out period with a standard bicarbonate
           haemodialysis using standard high-flux dialysis membrane identical to wash-in period.

      Measurement of the study end-points will be carried out at the end of 2-week wash-in period,
      each 4-week period and at the end of 4 week wash-out period.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, randomized, interventional, two parallel arm study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentration of uremic toxin p-cresol sulphate</measure>
    <time_frame>At the end of wash-in period (basal sample-baseline), at the end of first phase (4 weeks after baseline), at the end of second phase (8 weeks after baseline), at the end of wash-out period (12 weeks after baseline).</time_frame>
    <description>Blood for the laboratory measurements of serum total p-cresol sulphate concentration will be taken from the arterial line before the start of midweek hemodialysis procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of uremic toxins indoxyl sulfate</measure>
    <time_frame>At the end of wash-in period (basal sample-baseline), at the end of first phase (4 weeks after baseline), at the end of second phase (8 weeks after baseline), at the end of wash-out period (12 weeks after baseline).</time_frame>
    <description>Blood for the laboratory measurements of serum total indoxyl sulfate concentration will be taken from the arterial line before the start of midweek hemodialysis procedure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum concentration of uremic toxin trimethylamine N-oxide (TMAO)</measure>
    <time_frame>At the end of wash-in period (basal sample-baseline), at the end of first phase (4 weeks after baseline), at the end of second phase (8 weeks after baseline), at the end of wash-out period (12 weeks after baseline).</time_frame>
    <description>Blood for the laboratory measurements of serum TMAO concentration will be taken from the arterial line before the start of midweek hemodialysis procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum concentration of beta2-microglobulin</measure>
    <time_frame>At the end of wash-in period (basal sample-baseline), at the end of first phase (4 weeks after baseline), at the end of second phase (8 weeks after baseline), at the end of wash-out period (12 weeks after baseline).</time_frame>
    <description>Blood for the laboratory measurements of serum beta2-microglobulin concentration will be taken from the arterial line before the start of midweek hemodialysis procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum concentration of phosphate</measure>
    <time_frame>At the end of wash-in period (basal sample-baseline), at the end of first phase (4 weeks after baseline), at the end of second phase (8 weeks after baseline), at the end of wash-out period (12 weeks after baseline).</time_frame>
    <description>Blood for the laboratory measurements of serum phosphate concentration will be taken from the arterial line before the start of midweek hemodialysis procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum urea concentration</measure>
    <time_frame>At the end of wash-in period (basal sample-baseline), at the end of first phase (4 weeks after baseline), at the end of second phase (8 weeks after baseline), at the end of wash-out period (12 weeks after baseline).</time_frame>
    <description>Blood for the laboratory measurements of serum urea concentration will be taken from the arterial line before the start of midweek hemodialysis procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum albumin concentration</measure>
    <time_frame>At the end of wash-in period (basal sample-baseline), at the end of first phase (4 weeks after baseline), at the end of second phase (8 weeks after baseline), at the end of wash-out period (12 weeks after baseline).</time_frame>
    <description>Blood for the laboratory measurements of serum albumin concentration will be taken from the arterial line before the start of midweek hemodialysis procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Dialysis symptom index questionnaire score</measure>
    <time_frame>At the end of wash-in period (basal sample-baseline), at the end of first phase (4 weeks after baseline), at the end of second phase (8 weeks after baseline), at the end of wash-out period (12 weeks after baseline).</time_frame>
    <description>A validated questionnaire of 30 questions regarding the dialysis symptoms experienced during the last week. Unabbreviated scale title: Dialysis symptom index. Each of 30 items (symptoms) is ranked on a 5-point Likert scale. Minimal score: 0. Maximum score: 150. Higher scores mean worse outcomes (worse symptom burden).</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to finish 10 repetition sit to stand test</measure>
    <time_frame>At the end of wash-in period (basal sample-baseline), at the end of first phase (4 weeks after baseline), at the end of second phase (8 weeks after baseline), at the end of wash-out period (12 weeks after baseline).</time_frame>
    <description>This validated test measures lower limb strength. Participants are required to stand up and sit down 10 times from an armless chair as quickly as possible, the outcome is the time needed to perform the test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity level as measured by accelerometry</measure>
    <time_frame>At the end of wash-in period (basal sample-baseline), at the end of second phase (8 weeks after baseline), at the end of wash-out period (12 weeks after baseline).</time_frame>
    <description>Number of accelerometer counts in 7 days.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Haemodialysis</condition>
  <condition>Diet, Healthy</condition>
  <arm_group>
    <arm_group_label>Interventional arm - MCO dialysis membrane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of dialysis with MCO (Theranova) membrane then dialysis for 4 weeks with MCO membrane and increased fiber intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm - high-flux membrane haemodiafiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 weeks of high-flux membrane haemodiafiltration and 4 weeks of high-flux membrane haemodiafiltration and increased fiber intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>medium cut-off (MCO) dialysis membrane</intervention_name>
    <description>Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).</description>
    <arm_group_label>Interventional arm - MCO dialysis membrane</arm_group_label>
    <other_name>Theranova dialysis membrane (Baxter AG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary fiber mixture (Plantago Psyllium and Inulin)</intervention_name>
    <description>Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.</description>
    <arm_group_label>Control arm - high-flux membrane haemodiafiltration</arm_group_label>
    <arm_group_label>Interventional arm - MCO dialysis membrane</arm_group_label>
    <other_name>Kolon3aktiv fiber powder (manufacturer TOPNATUR s.r.o., Czech republic)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium propionate</intervention_name>
    <description>Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.</description>
    <arm_group_label>Control arm - high-flux membrane haemodiafiltration</arm_group_label>
    <arm_group_label>Interventional arm - MCO dialysis membrane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient on chronic hemodialysis or hemodiafiltration for at least 12 weeks,

          -  age 18 years old or more,

          -  a functioning arteriovenous fistula or graft as a permanent dialysis vascular access,

          -  being able to give an informed consent to participate in the survey;

        Exclusion Criteria:

          -  planned kidney transplantation, transition to peritoneal dialysis or to another
             dialysis center within 12 weeks of the start of the study,

          -  active chronic inflammation (e.g., an active autoimmune disease or an open wound),
             chronic ongoing infection or cancer in last 4 weeks,

          -  acute febrile illness in last 4 weeks,

          -  new cardiovascular or neurovascular event in last 4 weeks,

          -  a need for hospitalization in the last 4 weeks,

          -  clinically evident malnutrition and/or body mass index of 19 kg/m2 and/or loss of body
             weight for 5% in last 3 months,

          -  immunosuppressive treatment,

          -  expected survival of less than 1 year,

          -  pregnancy or breast-feeding,

          -  indication for dietary supplements to increase calorie and / or protein intake,

          -  specific indication for carrying out hemodiafiltration instead of hemodialysis as per
             attending physician,

          -  serum albumin concentration &lt;32 g/l at screening to enter the study,

          -  inability to follow the study diet or test procedures,

          -  rapid reduction of residual renal function in the period prior to entry into the
             study,

          -  intolerant of on-line haemodiafiltration (infusion intolerance);
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jernej Pajek, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Nephrology department, University Medical Centre Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jernej Pajek, MD, PhD</last_name>
    <phone>+38615228124</phone>
    <email>jernej.pajek@mf.uni-lj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tjaša Herič, MD</last_name>
    <phone>+38615228964</phone>
    <phone_ext>+38670861169</phone_ext>
    <email>tjasa.heric@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Dobre M, Meyer TW, Hostetter TH. Searching for uremic toxins. Clin J Am Soc Nephrol. 2013 Feb;8(2):322-7. doi: 10.2215/CJN.04260412. Epub 2012 Sep 27. Review.</citation>
    <PMID>23024165</PMID>
  </reference>
  <reference>
    <citation>Depner TA. Uremic toxicity: urea and beyond. Semin Dial. 2001 Jul-Aug;14(4):246-51. Review.</citation>
    <PMID>11489197</PMID>
  </reference>
  <reference>
    <citation>Mostovaya IM, Blankestijn PJ, Bots ML, Covic A, Davenport A, Grooteman MP, Hegbrant J, Locatelli F, Vanholder R, Nubé MJ; EUDIAL1 – an official ERA-EDTA Working Group. Clinical evidence on hemodiafiltration: a systematic review and a meta-analysis. Semin Dial. 2014 Mar;27(2):119-27. Review.</citation>
    <PMID>24738146</PMID>
  </reference>
  <reference>
    <citation>Wang AY, Ninomiya T, Al-Kahwa A, Perkovic V, Gallagher MP, Hawley C, Jardine MJ. Effect of hemodiafiltration or hemofiltration compared with hemodialysis on mortality and cardiovascular disease in chronic kidney failure: a systematic review and meta-analysis of randomized trials. Am J Kidney Dis. 2014 Jun;63(6):968-78. doi: 10.1053/j.ajkd.2014.01.435. Epub 2014 Mar 28. Review.</citation>
    <PMID>24685515</PMID>
  </reference>
  <reference>
    <citation>Zweigart C, Boschetti-de-Fierro A, Hulko M, Nilsson LG, Beck W, Storr M, Krause B. Medium cut-off membranes - closer to the natural kidney removal function. Int J Artif Organs. 2017 Jul 5;40(7):328-334. doi: 10.5301/ijao.5000603. Epub 2017 May 26.</citation>
    <PMID>28574113</PMID>
  </reference>
  <reference>
    <citation>Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M, Hulko M, Boehler T, Glomb MA, Liehr K, Henning C, Templin M, Trojanowicz B, Ulrich C, Werner K, Fiedler R, Girndt M. Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial. PLoS One. 2017 Jan 13;12(1):e0169024. doi: 10.1371/journal.pone.0169024. eCollection 2017.</citation>
    <PMID>28085888</PMID>
  </reference>
  <reference>
    <citation>Eloot S, Van Biesen W, Glorieux G, Neirynck N, Dhondt A, Vanholder R. Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients? PLoS One. 2013 Nov 13;8(11):e76838. doi: 10.1371/journal.pone.0076838. eCollection 2013.</citation>
    <PMID>24236005</PMID>
  </reference>
  <reference>
    <citation>Montemurno E, Cosola C, Dalfino G, Daidone G, De Angelis M, Gobbetti M, Gesualdo L. What would you like to eat, Mr CKD Microbiota? A Mediterranean Diet, please! Kidney Blood Press Res. 2014;39(2-3):114-23. doi: 10.1159/000355785. Epub 2014 Jul 29. Review.</citation>
    <PMID>25117687</PMID>
  </reference>
  <reference>
    <citation>Sirich TL. Dietary protein and fiber in end stage renal disease. Semin Dial. 2015 Jan-Feb;28(1):75-80. doi: 10.1111/sdi.12315. Epub 2014 Oct 16.</citation>
    <PMID>25319504</PMID>
  </reference>
  <reference>
    <citation>Claro LM, Moreno-Amaral AN, Gadotti AC, Dolenga CJ, Nakao LS, Azevedo MLV, de Noronha L, Olandoski M, de Moraes TP, Stinghen AEM, Pécoits-Filho R. The Impact of Uremic Toxicity Induced Inflammatory Response on the Cardiovascular Burden in Chronic Kidney Disease. Toxins (Basel). 2018 Sep 23;10(10). pii: E384. doi: 10.3390/toxins10100384.</citation>
    <PMID>30249039</PMID>
  </reference>
  <reference>
    <citation>Barrajón-Catalán E, Herranz-López M, Joven J, Segura-Carretero A, Alonso-Villaverde C, Menéndez JA, Micol V. Molecular promiscuity of plant polyphenols in the management of age-related diseases: far beyond their antioxidant properties. Adv Exp Med Biol. 2014;824:141-59. doi: 10.1007/978-3-319-07320-0_11. Review.</citation>
    <PMID>25038998</PMID>
  </reference>
  <reference>
    <citation>Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, Donahue SE, Asplin JR. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011 Feb;6(2):257-64. doi: 10.2215/CJN.05040610. Epub 2010 Dec 23.</citation>
    <PMID>21183586</PMID>
  </reference>
  <reference>
    <citation>Marzocco S, Fazeli G, Di Micco L, Autore G, Adesso S, Dal Piaz F, Heidland A, Di Iorio B. Supplementation of Short-Chain Fatty Acid, Sodium Propionate, in Patients on Maintenance Hemodialysis: Beneficial Effects on Inflammatory Parameters and Gut-Derived Uremic Toxins, A Pilot Study (PLAN Study). J Clin Med. 2018 Sep 30;7(10). pii: E315. doi: 10.3390/jcm7100315.</citation>
    <PMID>30274359</PMID>
  </reference>
  <reference>
    <citation>Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, Schneider A, Wanner C, Rosenkranz AR, Krieter DH. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2017 Jan 1;32(1):165-172. doi: 10.1093/ndt/gfw310.</citation>
    <PMID>27587605</PMID>
  </reference>
  <reference>
    <citation>Krishnasamy R, Hawley CM, Jardine MJ, Roberts MA, Cho YJ, Wong MG, Heath A, Nelson CL, Sen S, Mount PF, Pascoe EM, Darssan D, Vergara LA, Paul-Brent PA, Toussaint ND, Johnson DW, Hutchison CA. Design and methods of the REMOVAL-HD study: a tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HaemoDialysis patients. BMC Nephrol. 2018 Apr 17;19(1):89. doi: 10.1186/s12882-018-0883-8.</citation>
    <PMID>29665795</PMID>
  </reference>
  <reference>
    <citation>Borges NA, Barros AF, Nakao LS, Dolenga CJ, Fouque D, Mafra D. Protein-Bound Uremic Toxins from Gut Microbiota and Inflammatory Markers in Chronic Kidney Disease. J Ren Nutr. 2016 Nov;26(6):396-400. doi: 10.1053/j.jrn.2016.07.005.</citation>
    <PMID>27751361</PMID>
  </reference>
  <reference>
    <citation>Chapdelaine I, de Roij van Zuijdewijn CL, Mostovaya IM, Lévesque R, Davenport A, Blankestijn PJ, Wanner C, Nubé MJ, Grooteman MP; EUDIAL Group, Blankestijn PJ, Davenport A, Basile C, Locatelli F, Maduell F, Mitra S, Ronco C, Shroff R, Tattersall J, Wanner C. Optimization of the convection volume in online post-dilution haemodiafiltration: practical and technical issues. Clin Kidney J. 2015 Apr;8(2):191-8. doi: 10.1093/ckj/sfv003. Epub 2015 Feb 16.</citation>
    <PMID>25815176</PMID>
  </reference>
  <reference>
    <citation>Pajek J, Kveder R, Bren A, Gucek A, Ihan A, Osredkar J, Lindholm B. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Perit Dial Int. 2008 Jan-Feb;28(1):44-52.</citation>
    <PMID>18178947</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Jernej Pajek</investigator_full_name>
    <investigator_title>Associate Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>medium cut-off dialysis membrane</keyword>
  <keyword>p-cresol sulphate</keyword>
  <keyword>indoxyl-sulphate</keyword>
  <keyword>trimethylamine-N-oxide (TMAO)</keyword>
  <keyword>hemodiafiltration</keyword>
  <keyword>uremic toxins</keyword>
  <keyword>dietary fibre</keyword>
  <keyword>end stage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psyllium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to share IPD that underline results published in the manuscripts reporting study results.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From the time of publication of associated manuscripts for 10 years.</ipd_time_frame>
    <ipd_access_criteria>Available on demand from the investigators.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

